



NEWS RELEASE

BIOSYENT DECLARES FIRST QUARTER 2026 DIVIDEND

FOR IMMEDIATE RELEASE

JANUARY 29, 2026

MISSISSAUGA, ONTARIO (January 29, 2026) BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of \$0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of \$0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 11,263,255 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum

President and CEO

BioSyent Inc.

E-Mail: investors@biosyent.com

Phone: 905-206-0013

Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.